NCT04840589 - Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 2, 2022

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions

Metastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmRecurrent Platinum-Resistant Ovarian CarcinomaRefractory Ovarian Carcinoma

Interventions

DRUG

BET Bromodomain Inhibitor ZEN-3694

Given PO

PROCEDURE

Biopsy Procedure

Undergo a biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo a CT scan

BIOLOGICAL

Ipilimumab

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

BIOLOGICAL

Nivolumab

Given IV

PROCEDURE

Positron Emission Tomography

Undergo a PET scan

PROCEDURE

X-Ray Imaging

Undergo x-ray

Trial Locations (9)

10029

ACTIVE_NOT_RECRUITING

Mount Sinai Hospital, New York

10461

RECRUITING

Montefiore Medical Center-Einstein Campus, The Bronx

RECRUITING

Montefiore Medical Center-Weiler Hospital, The Bronx

10467

RECRUITING

Montefiore Medical Center - Moses Campus, The Bronx

15232

RECRUITING

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

20892

ACTIVE_NOT_RECRUITING

National Cancer Institute Developmental Therapeutics Clinic, Bethesda

ACTIVE_NOT_RECRUITING

National Institutes of Health Clinical Center, Bethesda

44106

SUSPENDED

Case Western Reserve University, Cleveland

97239

RECRUITING

Oregon Health and Science University, Portland

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH